BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29356285)

  • 1. Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yamamoto M; Hori T; Igarashi K; Shimada H; Tsutsumi H
    Pediatr Int; 2018 Jan; 60(1):85-87. PubMed ID: 29356285
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
    Pirosa MC; Leotta S; Cupri A; Stella S; Martino EA; Scalise L; Sapienza G; Calafiore V; Mauro E; Spadaro A; Vigneri P; Di Raimondo F; Milone G
    Chemotherapy; 2018; 63(4):220-224. PubMed ID: 30372691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
    Renzi D; Marchesi F; De Angelis G; Elia L; Salvatorelli E; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Arcese W; Mengarelli A;
    Chemotherapy; 2017; 62(1):58-61. PubMed ID: 27618144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
    Leotta S; Markovic U; Pirosa MC; Stella S; Tringali S; Martino M; Specchia G; Carluccio P; Risitano AM; Grimaldi F; Vigna E; Palmieri F; Palmieri R; Annunziata M; Pisapia G; Palazzo G; Milone GA; Pelle AC; Scalise L; Di Giorgio MA; Bulla A; Leotta V; Di Raimondo F; Milone G
    Ann Hematol; 2021 Jul; 100(7):1743-1753. PubMed ID: 33774681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
    He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
    Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Short NJ; Konopleva M; Kadia T; Kebriaei P; Daver N; Huang X; Masarova L; Cook R; Jain N; Jabbour E; Kantarjian H; Ravandi F
    Am J Hematol; 2021 Jul; 96(7):E229-E232. PubMed ID: 33780038
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sanford DS; Kantarjian H; O'Brien S; Jabbour E; Cortes J; Ravandi F
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):365-73. PubMed ID: 25764322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib.
    Tachibana T; Tanaka M; Noguchi Y; Najima Y; Sadato D; Harada Y; Tamai Y; Doki N; Nakajima H
    Hematology; 2024 Dec; 29(1):2360843. PubMed ID: 38828928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
    Short NJ; Jabbour E; Nasr LF; Jain N; Haddad FG; Issa GC; Sasaki K; Senapati J; Kebriaei P; Garris R; Konopleva M; Ravandi F; Kantarjian H
    Am J Hematol; 2024 Jul; 99(7):1423-1426. PubMed ID: 38607091
    [No Abstract]   [Full Text] [Related]  

  • 14. Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
    Petrungaro A; Gentile M; Mazzone C; Greco R; Uccello G; Recchia AG; De Stefano L; Bossio S; Palummo A; Morelli R; Musolino C; Morabito F; Vigna E
    Chemotherapy; 2017; 62(6):353-356. PubMed ID: 28810255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Nanno S; Matsumoto K; Nakamae M; Okamura H; Nishimoto M; Hirose A; Koh H; Nakashima Y; Nakane T; Morita K; Hino M; Nakamae H
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):813-819.e1. PubMed ID: 32800519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
    El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
    Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with ponatinib in paediatric patients with leukaemia.
    Rossoff J; Huynh V; Rau RE; Macy ME; Sulis ML; Schultz KR; Burke MJ; Athale U; O'Brien MM; Gregory JJ; van der Sluis IM; Keller FG; Zwaan CM; Suttorp M; Hijiya N
    Br J Haematol; 2020 Apr; 189(2):363-368. PubMed ID: 31975387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.
    Tachibana T; Koyama S; Andou T; Ishiyama Y; Tanaka M; Nakajima H; Kanamori H
    Int J Hematol; 2019 Feb; 109(2):162-168. PubMed ID: 30511314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia.
    Marchesi F; Salvatorelli E; Renzi D; Mengarelli A; Minotti G; Menna P
    Br J Haematol; 2019 Oct; 187(1):e15-e17. PubMed ID: 31368155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.